Cite
HARVARD Citation
Kelley, R. et al. (2021). Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of clinical oncology. 39 (27), pp. 2991-3001. [Online].